Todd Chappell

Chappell is a 20-year veteran of the biopharma industry with experience running multiple drug development programs from the discovery stage through to clinical trials.

​November 14, 2019, Baltimore, MD–Rasio Therapeutics, Inc., a biopharmaceutical company that develops novel medicines using cutting-edge computer-aided drug design technology, today announced the appointment of Todd Chappell, a veteran MedTech and pharmaceutical industry executive, as the company’s CEO.

​Chappell has significant experience running early-stage life science programs from the discovery stage through to clinical trials. In his most recent role, Chappell served as CEO of Perceptive Navigation, LLC, an early-stage medical device company where he raised over $5 million in seed financing and non-dilutive grants from the National Institutes of Health (NIH). Under Chappell’s leadership, Perceptive advanced its technology from the concept stage through to its first-in-human clinical study.

Chappell also previously led Shape Pharmaceuticals, Inc., a portfolio company of HealthCare Ventures, LLC, that developed a novel HDAC inhibitor for the topical treatment of Cutaneous T-Cell Lymphoma and other proliferative diseases of the skin. The shape was sold to Tetralogic Pharmaceuticals, Inc. (TLOG) in April 2014.

​In addition, Chappell was selected to be the first Entrepreneur-in-Residence established at the National Institutes of Health (NIH) through a private-public partnership led by BioHealth Innovation, Inc. Chappell worked with scientists to develop and commercialize technologies and served in key management roles for four early-stage biotechnology companies in Maryland. Chappell holds a BS in Biology from the University of California at Los Angeles and an MBA from Boston University.